Yana G. Najjar
机构: UPMC Hillman Cancer Center
每年引用次数
引用次数
引用: 2,564
H-指数: 17
I10-指数 : 21
出版物: 84
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Diwakar Davar , Amiran K Dzutsev , John A McCulloch , Richard R Rodrigues
Science 371 ( 6529) 595 -602
482
2021
A post-COVID survey of current and future parents among faculty, trainees, and research staff at an NCI-designated cancer center.
Annie P Im , Yana G Najjar , Todd Bear , Devin Dressman
Journal of Clinical Oncology 39 ( 15_suppl) 11002 -11002
2021
Pembrolizumab: pharmacology and therapeutics review
Yana G Najjar , John M Kirkwood
Am J Hematol Oncol 20 17 -9
9
2015
Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
Yana G Najjar
Journal for Immunotherapy of Cancer 9 ( 7)
4
2021
614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification
Maria Vieito , E Garralda , Inderjit Mehmi , C Gaudy Marqueste
Annals of Oncology 35 S492 -S492
2024
LUMINOS-102: PVSRIPO with or without immune checkpoint blockade in unresectable anti-PD-1 refractory melanoma
Ding Wang , C Lance Cowey , Evan Pisick , John Kirkwood
35 ( 10) 150 -150
2021
PD-1 expression level on T cell subsets is a crucial factor forming a novel mechanism for designing immune therapeutic approaches using PD-1 binding ligand
Mikayel Mkrtichyan , Yana G Najjar , Estella C Raulfs , Linda Liu
CANCER RESEARCH 72
2012
1325 T cell and immune activation from a phase 1 study of STK-012, a first-in-class IL-2R α/β selective partial agonist in advanced solid tumors
Adam J Schoenfeld , Benjamin Izar , Alexander Spira , Dmitriy Zamarin
Journal for ImmunoTherapy of Cancer 12 ( Suppl 2)
2024
Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma.
Yana George Najjar , Paul Elson , Laura S. Wood , Jorge A. Garcia
Journal of Clinical Oncology 31 406 -406
7
2013
A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma
Y.G. Najjar , K. Mittal , P. Elson , L. Wood
European Journal of Cancer 50 ( 6) 1084 -1089
128
2014
1091P Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600-mutated stage III/IV melanoma
JS Weber , W Haque , SN Markovic , AKS Salama
Annals of Oncology 34 S657 -S658
2023
Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?(vol 9, e002820, 2021)
YG Najjar
JOURNAL FOR IMMUNOTHERAPY OF CANCER 10 ( 2)
2022
P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets
Nils-Petter Rudqvist , Roberta Zappasodi , Daniel Wells , Vésteinn Thorsson
Journal for ImmunoTherapy of Cancer 8
2020
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge" (December 4th-5th, 2019, Naples, Italy).
Paolo A. Ascierto , Lisa H. Butterfield , Katie Campbell , Bruno Daniele
Journal of Translational Medicine 19 ( 1) 13
2021
Thick Melanoma Is Associated with Low Melanoma Knowledge and Low Perceived Health Competence, but Not Delays in Care
Sophia H. Zhang , Rebecca Liu , Nalyn Siripong , John M. Kirkwood
Journal of The American Academy of Dermatology 83 ( 2) 587 -590
1
2020
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors
Elaine Shum , Adil Daud , Matthew Reilley , Yana Najjar
Journal for ImmunoTherapy of Cancer 8
1
2020
435 A phase II trial of nivolumab plus axitinib in patients with anti-PD1 refractory advanced melanoma
Saba Shaikh , Yan Zang , Hong Wang , Xi Yang
Journal for ImmunoTherapy of Cancer 8
2020
Metastatic Melanoma With Sebocyte-Like Melanocytes and Widespread Visceral Involvement.
Li-Wei Chang , Viktoryia Kazlouskaya , Jenna R. Bordelon , Marion A. Hughes
Dermatology practical & conceptual 10 ( 2)
2020
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma
Somak Roy , Dinesh Pradhan , Wayne L Ernst , Stephanie Mercurio
Modern Pathology 30 ( 8) 1133 -1143
21
2017
523 Preliminary clinical experience with XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors
Elaine Shum , Matthew Reilley , Yana Najjar , Adil Daud
Journal for ImmunoTherapy of Cancer 9 ( Suppl 2)
14
2021